Vascular Designs Receives CE Mark Approval for Its IsoFlow™ Infusion Catheter to Target Cancerous Tumors
(Logo: http://photos.prnewswire.com/prnh/20111114/SF06426LOGO)
"CE Mark approval is an important confirmation of the substantial benefits that patients will receive from targeted treatment of cancerous tumors," said Robert Goldman , CEO of Vascular Designs, Inc. and creator of the IsoFlow Infusion Catheter. "Directing treatment to specific locations increases the number of treatment options allowing better access to tumors and may reduce the discomfort to patients associated with the systemic application of chemotherapy."
About Vascular Designs, Inc.
Vascular Designs, Inc. is a medical device company located in San Jose, California . Founder Robert Goldman developed the idea behind Vascular Designs and its innovative IsoFlow™ Infusion Catheter. His personal experience of watching loved ones suffer from, and succumb to cancer, had a profound influence on the creation of IsoFlow.
With the IsoFlow Infusion Catheter's unique design, medications can be pushed into areas that could not previously be treated directly. According to numerous studies, this type of approach to delivery can increase drug concentrations at targeted sites while reducing systemic exposure, potentially improving treatment outcomes.
The IsoFlow Infusion Catheter is in use in hospitals throughout the United States .
For more information on Vascular Designs, Inc., please visit www.vasculardesigns.com.
To view an animation illustrating the IsoFlow Infusion Catheter in action and other press materials, please visit http://www.vasculardesigns.com/news.htm.
Media Contact: Dan Orloff , Orloff Williams Partners, San Jose , 408-202-3188, dorloff@orloffwilliams.com